Clinical Trial Update: UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 UNITY 2 evaluates a fixed-dose DCV+ASV+BMS-791325 regimen (DCV 3DAA) with or without RBV for 12 weeks in chronic hepatitis C genotype 1 with compensated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daklinza (Daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED